Tailoring nanoplatforms for depression applications

Depression is a common psychiatric disorder associated with high recurrence rates and a substantial global disease burden. Although conventional antidepressant therapies remain the main treatment option, their clinical efficacy is often limited by delayed onset, inadequate brain targeting, systemic adverse effects, and considerable interindividual variability. These limitations highlight the need for more efficient drug delivery strategies for the central nervous system. Nanomedicine has emerged as a promising approach to improve antidepressant delivery and therapeutic efficacy. Nanocarriers can enhance drug solubility and stability, prolong systemic circulation, and facilitate transport across the blood–brain barrier (BBB), thereby increasing drug accumulation in the brain. Recent advances in nanotechnology-based drug delivery systems, including lipid-based nanocarriers and polymeric nanoparticles, have demonstrated potential for controlled drug release and targeted brain delivery while modulating key pathological processes involved in depression. Overall, nanomedicine represents a promising strategy for improving the precision and effectiveness of antidepressant therapy, although further studies are required to address challenges related to biosafety, large-scale production, and clinical translation.